enteralogo.png
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
March 26, 2024 08:30 ET | Entera Bio Ltd.
JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American...
enteralogo.png
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
March 08, 2024 16:05 ET | Entera Bio Ltd.
JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results...
enteralogo.png
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 04, 2024 08:30 ET | Entera Bio Ltd.
JERUSALEM, March 04, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that it received...
Osteoporosis Drugs Market is Projected to Develop at a CAGR of 3.5% from 2023 to 2033 | Persistence Market Research
January 16, 2024 03:00 ET | Persistence Market Research
New York, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Market Overview: The Osteoporosis Drugs Market is a rapidly evolving sector within the pharmaceutical industry, primarily driven by the growing aging...
enteralogo.png
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform
November 29, 2023 08:30 ET | Entera Bio Ltd.
JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reported...
enteralogo.png
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
November 14, 2023 07:30 ET | Entera Bio Ltd.
JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins,...
enteralogo.png
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis
November 09, 2023 14:30 ET | Entera Bio Ltd.
JERUSALEM, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reports...
RationalStat Logo 1.png
Osteoporosis Treatment Market to Hit Market Size of US$ 16.6 Billion by 2030, Says a Market Report by RationalStat
November 09, 2023 01:21 ET | Rationalstat LLC
Wilmington Delaware, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Global Osteoporosis Treatment Market is valued at US$ 12.0 billion in 2023 and is expected to grow at a significant CAGR of over 4.8% over the...
TIP_link_300x300.jpg
Vitamin K2 Market Worth $1.16 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
October 16, 2023 07:52 ET | The Insight Partners
Pune, India, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Vitamin K2, also known as menaquinone, is a part of vitamin K family. It plays an important role in keeping bones and heart healthy. MK-4 and MK-7 are...
Rani-Logo.jpg
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
October 12, 2023 16:05 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...